{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T05:27:40Z","timestamp":1789018060172,"version":"build-2803163510"},"reference-count":34,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2008,3,7]],"date-time":"2008-03-07T00:00:00Z","timestamp":1204848000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,5,15]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Response rates to second\u2010line chemotherapy in recurrent high\u2010grade glial tumors are low and new effective treatments are needed. The objective of this study was to evaluate response rates and tolerability of chemotherapy with bevacizumab and irinotecan in recurrent high\u2010grade gliomas.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty patients with recurrent gliomas were treated with bevacizumab 5 mg\/kg and irinotecan 125 mg\/m<jats:sup>2<\/jats:sup> every 2 weeks. The response was evaluated by gadolinium\u2010enhanced magnetic resonance imaging performed every 4 cycles of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The patients received 1 to 22 cycles of treatment. Nine of 19 patients available for response evaluation (47.3%) showed an objective radiologic response: 2 patients (10.5%) a complete response (CR), and 7 patients (36.8%) a partial response (PR). Two additional patients showed stable disease (SD) for 2 and 6 months, respectively. Eight patients developed rapid progression after 1 to 4 cycles of treatment. Median time to progression on treatment was 4.7 months. The 6\u2010month progression\u2010free survival (PFS) and overall survival (OS) were 25% and 55%, respectively. The adverse effects were mild and in all but 2 cases were no more than grade 2. There were no thrombotic complications or significant bleeding other than epistaxis.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The preliminary data show a promising high response rate of recurrent high\u2010grade gliomas to chemotherapy with bevacizumab and irinotecan. The regimen is associated with minimal toxicity. Cancer 2008. \u00a9 2008 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.23401","type":"journal-article","created":{"date-parts":[[2008,3,7]],"date-time":"2008-03-07T18:46:33Z","timestamp":1204915593000},"page":"2267-2273","source":"Crossref","is-referenced-by-count":128,"title":["Treatment with bevacizumab and irinotecan for recurrent high\u2010grade glial tumors"],"prefix":"10.1002","volume":"112","author":[{"given":"Felix","family":"Bokstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shulim","family":"Shpigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah T.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2008,4,28]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08091-1"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa043330"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.8.2572"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.08.110"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0773"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1215\/S1522851705000451"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051918"},{"key":"e_1_2_5_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji161"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc053459"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6603669"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11060-006-9302-2"},{"key":"e_1_2_5_13_2","unstructured":"Stark\u2010VanceV. Bevacizumab and CPT\u201011 in the treatment of relapsed malignant glioma.World Federation of Neuro\u2010Oncology Meeting2005:91."},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-2309"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002800050794"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11306"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.7.1277"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000208958.29600.87"},{"key":"e_1_2_5_19_2","unstructured":"RTOG 0625. A randomized phase II trial of bevacizumab with irinotecan or bevacizumab with temozolomide in recurrent glioblastoma. Available from URL:http:\/\/www.rtog.org\/members\/protocols\/0625\/0625.pdfAccessed October 6 2007."},{"issue":"5","key":"e_1_2_5_20_2","first-page":"9","article-title":"Irinotecan: promising activity in the treatment of malignant glioma","volume":"17","author":"Reardon DA","year":"2003","journal-title":"Oncology (Williston Park)."},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000218"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1215\/15228517-2005-010"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1215\/S1152851703000413"},{"issue":"21","key":"e_1_2_5_24_2","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1093\/ajhp\/61.suppl_5.S21","article-title":"Overview of bevacizumab: a new cancer therapeutic strategy targeting vascular endothelial growth factor","volume":"61","author":"Ignoffo RJ","year":"2004","journal-title":"Am J Health Syst Pharm."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.843"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.3.851"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2003.08.013"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021491"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.10.066"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.11.022"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.09.6305"},{"key":"e_1_2_5_33_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.098"},{"key":"e_1_2_5_35_2","doi-asserted-by":"crossref","unstructured":"RavalS HwangS DorsettL.Bevacizumab and irinotecan in patients with recurrent glioblastoma multiforme. 43rd ASCO Annual Meeting.2007;25:2078.","DOI":"10.1200\/jco.2007.25.18_suppl.2078"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23401","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.23401","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T18:05:41Z","timestamp":1760292341000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23401"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4,28]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2008,5,15]]}},"alternative-id":["10.1002\/cncr.23401"],"URL":"https:\/\/doi.org\/10.1002\/cncr.23401","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4,28]]}}}